Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.50 |
| ▸ | APLNR | P35414 | 1/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 4/20 | 0.49 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSH | P09668 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.47 |
| ▸ | GLP1R | P43220 | 1/20 | 0.47 |
| ▸ | CALCR | P30988 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19780600 | 1.00 | C5AR1 (0.52) | C5AR1AGTR1EPHA2APLNRAGTR2 | |
| SCHEMBL17274190 | 0.97 | C5AR1 (0.51) | C5AR1AGTR1EPHA2APLNRAGTR2 | |
| SCHEMBL17287126 | 0.97 | C5AR1 (0.51) | C5AR1AGTR1EPHA2APLNRAGTR2 | |
| SCHEMBL18699989 | 0.93 | AGTR1 (0.51) | C5AR1AGTR1AGTR2F2NTSR1 | |
| SCHEMBL18699890 | 0.93 | C5AR1 (0.49) | C5AR1AGTR1EPHA2APLNRAGTR2 | |
| SCHEMBL17287131 | 0.93 | AGTR1 (0.51) | C5AR1AGTR1EPHA2APLNRAGTR2 | |
| SCHEMBL17274210 | 0.90 | AGTR1 (0.49) | C5AR1AGTR1APLNRAGTR2F2 | |
| SCHEMBL17287128 | 0.90 | AGTR1 (0.49) | C5AR1AGTR1APLNRAGTR2F2 | |
| SCHEMBL17274223 | 0.90 | AGTR1 (0.49) | C5AR1AGTR1APLNRAGTR2F2 | |
| SCHEMBL18699899 | 0.89 | AGTR1 (0.56) | C5AR1AGTR1EPHA2APLNRAGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016301-A1 | Synthesis of Beta-Arrestin Effectors | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016301-A1 | Synthesis of Beta-Arrestin Effectors | ARRB1, ADRB1, ADRB3 | C5AR1 1182/4885AGTR1 98/4885EPHA2 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.